Next earnings date: 18 Aug 2025
Talis Biomedical Corporation – NASDAQ:TLIS
Talis Biomedical stock price today
Talis Biomedical stock price monthly change
Talis Biomedical stock price quarterly change
Talis Biomedical stock price yearly change
Talis Biomedical key metrics
Market Cap | 3.13M |
Enterprise value | N/A |
P/E | -0.11 |
EV/Sales | -11.00 |
EV/EBITDA | 0.48 |
Price/Sales | 1.66 |
Price/Book | 0.10 |
PEG ratio | N/A |
EPS | -31.44 |
Revenue | 348K |
EBITDA | -55.74M |
Income | -57.21M |
Revenue Q/Q | -46.71% |
Revenue Y/Y | -76.42% |
Profit margin | -1128.66% |
Oper. margin | -2299.45% |
Gross margin | -73.25% |
EBIT margin | -2299.45% |
EBITDA margin | -16019.25% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTalis Biomedical stock price history
Talis Biomedical stock forecast
Talis Biomedical financial statements
| Jun 2023 | 48K | -15.03M | -31320.83% |
|---|---|---|---|
| Sep 2023 | 76K | -15.68M | -20634.21% |
| Dec 2023 | 151K | -13.46M | -8913.91% |
| Mar 2024 | 73K | -13.03M | -17856.16% |
| Sep 2025 | 400K | -232.25M | -58063.97% |
|---|---|---|---|
| Oct 2025 | 400K | -13.35M | -3338.91% |
| Dec 2025 | 12.6M | -11.69M | -92.83% |
| Dec 2025 | 12.6M | -11.71M | -92.98% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 123076000 | 26.91M | 21.86% |
|---|---|---|---|
| Sep 2023 | 107228000 | 25.67M | 23.94% |
| Dec 2023 | 98340000 | 29.22M | 29.72% |
| Mar 2024 | 82494000 | 25.81M | 31.29% |
| Jun 2023 | -14.27M | -485K | 0 |
|---|---|---|---|
| Sep 2023 | -11.14M | -70K | 0 |
| Dec 2023 | -11.35M | 93K | 0 |
| Mar 2024 | -6.42M | 30K | 2K |
Talis Biomedical alternative data
| Aug 2023 | 102 |
|---|---|
| Sep 2023 | 102 |
| Oct 2023 | 102 |
| Nov 2023 | 102 |
| Dec 2023 | 102 |
| Jan 2024 | 102 |
| Feb 2024 | 102 |
| Mar 2024 | 102 |
| Apr 2024 | 102 |
| May 2024 | 99 |
| Jun 2024 | 99 |
| Jul 2024 | 99 |
Talis Biomedical other data
| Period | Buy | Sel |
|---|---|---|
| Feb 2021 | 6639000 | 0 |
| May 2021 | 20000 | 0 |
| Aug 2021 | 0 | 27502 |
| Nov 2021 | 50000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | BAKER BROS. ADVISORS LP director, 10 percent owner | Common Stock | 50,000 | $4.37 | $218,250 | ||
Option | RAMAKRISHNAN RAMESH | Common Stock | 52,355 | $1.5 | $78,533 | ||
Sale | RAMAKRISHNAN RAMESH | Common Stock | 27,502 | $7.66 | $210,665 | ||
Option | RAMAKRISHNAN RAMESH | Stock Option (right to buy) | 43,614 | $1.5 | $65,421 | ||
Purchase | SCOTT RANDAL W. | Common stock | 11,000 | $10.11 | $111,210 | ||
Purchase | SCOTT RANDAL W. | Common stock | 9,000 | $10.16 | $91,440 | ||
Purchase | FLICK KAREN E. | Common Stock | 2,000 | $16 | $32,000 | ||
Purchase | LIU DOUGLAS | Common Stock | 4,000 | $16 | $64,000 | ||
Purchase | MOODY JOHN ROGER JR | Common Stock | 1,700 | $16 | $27,200 | ||
Purchase | POSARD MATTHEW L. | Common Stock | 62,500 | $16 | $1,000,000 |
| Patent |
|---|
Application Filling date: 17 Aug 2020 Issue date: 8 Sep 2022 |
Application Filling date: 24 Jul 2020 Issue date: 11 Aug 2022 |
Application Filling date: 12 Oct 2021 Issue date: 3 Feb 2022 |
Application Filling date: 14 Jul 2020 Issue date: 20 Jan 2022 |
Application Filling date: 14 Apr 2021 Issue date: 2 Dec 2021 |
Application Filling date: 20 May 2021 Issue date: 4 Nov 2021 |
Application Filling date: 22 Mar 2019 Issue date: 28 Oct 2021 |
Application Filling date: 9 May 2019 Issue date: 30 Sep 2021 |
Application Filling date: 25 Jun 2020 Issue date: 23 Sep 2021 |
Application Filling date: 2 Nov 2020 Issue date: 19 Aug 2021 |
| Quarter | Transcript |
|---|---|
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 14 May 2023 | Q1 2023 Earnings Call Transcript |
| Q2 2022 5 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q4 2021 15 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Brian Coe M.B.A. (1969) Co-Founder & Advisor | $377,490 |
| Mr. Douglas Liu (1962) Chief Operating Officer | $255,620 |
Mr. Robert Kelley MBA (1972) Chief Executive Officer & Director | $246,430 |
Dr. Rustem F. Ismagilov Ph.D. (1974) Co-Founder, Chairman of Scientific Advisory Board & Director | $75,000 |
-
What's the price of Talis Biomedical stock today?
One share of Talis Biomedical stock can currently be purchased for approximately $1.5.
-
When is Talis Biomedical's next earnings date?
Talis Biomedical Corporation is estimated to report earnings on Monday, 18 Aug 2025.
-
Does Talis Biomedical pay dividends?
No, Talis Biomedical does not pay dividends.
-
How much money does Talis Biomedical make?
Talis Biomedical has a market capitalization of 3.13M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 88.72% to 412K US dollars.
-
What is Talis Biomedical's stock symbol?
Talis Biomedical Corporation is traded on the NASDAQ under the ticker symbol "TLIS".
-
What is Talis Biomedical's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Talis Biomedical?
Shares of Talis Biomedical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Talis Biomedical's key executives?
Talis Biomedical's management team includes the following people:
- Mr. Brian Coe M.B.A. Co-Founder & Advisor(age: 56, pay: $377,490)
- Mr. Douglas Liu Chief Operating Officer(age: 63, pay: $255,620)
- Mr. Robert Kelley MBA Chief Executive Officer & Director(age: 53, pay: $246,430)
- Dr. Rustem F. Ismagilov Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Director(age: 51, pay: $75,000)
-
Is Talis Biomedical founder-led company?
Yes, Talis Biomedical is a company led by its founders Mr. Brian Coe M.B.A. and Dr. Rustem F. Ismagilov Ph.D..
-
How many employees does Talis Biomedical have?
As Jul 2024, Talis Biomedical employs 99 workers, which is 3% less then previous quarter.
-
When Talis Biomedical went public?
Talis Biomedical Corporation is publicly traded company for more then 4 years since IPO on 12 Feb 2021.
-
What is Talis Biomedical's official website?
The official website for Talis Biomedical is talisbio.com.
-
Where are Talis Biomedical's headquarters?
Talis Biomedical is headquartered at 230 Constitution Drive, Menlo Park, CA.
-
How can i contact Talis Biomedical?
Talis Biomedical's mailing address is 230 Constitution Drive, Menlo Park, CA and company can be reached via phone at +65 04333000.
Talis Biomedical company profile:
Talis Biomedical Corporation
talisbio.comNASDAQ
99
Medical - Devices
Healthcare
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Menlo Park, CA 94025
CIK: 0001584751
ISIN: US87424L2079
CUSIP: 87424L108
